Epidemiology and Management of Kawasaki Disease

被引:46
作者
Luca, Nadia J. C. [1 ,2 ]
Yeung, Rae S. M. [2 ,3 ,4 ]
机构
[1] Hosp Sick Children, Div Rheumatol, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, Dept Pediat, Toronto, ON, Canada
[3] Univ Toronto, Dept Immunol, Toronto, ON, Canada
[4] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada
关键词
INTRAVENOUS GAMMA-GLOBULIN; STEROID PULSE THERAPY; MACROPHAGE ACTIVATION SYNDROME; CORONARY-ARTERY INVOLVEMENT; ADDITIONAL IMMUNE GLOBULIN; AMERICAN-HEART-ASSOCIATION; LONG-TERM MANAGEMENT; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; NATIONWIDE SURVEY; DIFFERENTIAL-DIAGNOSIS;
D O I
10.2165/11631440-000000000-00000
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Kawasaki disease (KD) is an acute systemic vasculitis affecting young children and is rising in incidence worldwide. It is most common in children <5 years of age, males and those of Asian ethnicity. It is an important cause of acquired heart disease in children. Standard treatment with high-dose aspirin (acetylsalicylic acid; ASA) and intravenous immune globulin (IVIG) has been shown to decrease the rate of coronary artery aneurysm development. Anticoagulation has an important place in the management of KD, although guidance based on evidence is lacking. Treatment of refractory KD is an area under intense study and may include IVIG, corticosteroids and/or tumour necrosis factor (TNF)-alpha inhibitors among immunosuppressive agents. Acute complications of KD include myocarditis/KD shock syndrome and macrophage activation syndrome, which necessitate appropriate awareness in order to initiate proper management.
引用
收藏
页码:1029 / 1038
页数:10
相关论文
共 56 条
[1]   Risk factors for nonresponse to therapy in Kawasaki disease [J].
Ashouri, Negar ;
Takahashi, Masato ;
Dorey, Frederick ;
Mason, Wilbert .
JOURNAL OF PEDIATRICS, 2008, 153 (03) :365-368
[2]   Salicylate for the treatment of Kawasaki disease in children [J].
Baumer, J. H. ;
Love, S. J. L. ;
Gupta, A. ;
Haines, L. C. ;
Maconochie, I ;
Dua, J. S. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (04)
[3]   Infections and Kawasaki disease: Implications for coronary artery outcome [J].
Benseler, SM ;
McCrindle, BW ;
Silverman, ED ;
Tyrrell, PN ;
Wong, J ;
Yeung, RSM .
PEDIATRICS, 2005, 116 (06) :E760-E766
[4]  
Breunis WB, 2010, THESIS U AMSTERDAM
[5]   Infliximab Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease [J].
Burns, Jane C. ;
Best, Brookie M. ;
Mejias, Asuncion ;
Mahony, Lynn ;
Fixler, David E. ;
Jafri, Hasan S. ;
Melish, Marian E. ;
Jackson, Mary Anne ;
Asmar, Basim I. ;
Lang, David J. ;
Connor, James D. ;
Capparelli, Edmund V. ;
Keen, Monica L. ;
Mamun, Khalid ;
Keenan, Gregory F. ;
Ramilo, Octavio .
JOURNAL OF PEDIATRICS, 2008, 153 (06) :833-838
[6]   Infliximab treatment for refractory Kawasaki syndrome [J].
Burns, JC ;
Mason, WH ;
Hauger, SB ;
Janai, H ;
Bastian, JF ;
Wohrley, JD ;
Balfour, I ;
Shen, CA ;
Michel, ED ;
Shulman, ST ;
Melish, ME .
JOURNAL OF PEDIATRICS, 2005, 146 (05) :662-667
[7]   HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AT INITIATION OF KAWASAKI DISEASE AND THEIR DIFFERENTIAL DIAGNOSIS [J].
Chen, Yinghu ;
Shang, Shiqiang ;
Zhang, Chenmei ;
Liu, Tao ;
Yang, Zihao ;
Tang, Yongmin .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2010, 27 (03) :244-249
[8]   Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease [J].
Choueiter, Nadine F. ;
Olson, Aaron K. ;
Shen, Danny D. ;
Portman, Michael A. .
JOURNAL OF PEDIATRICS, 2010, 157 (06) :960-U148
[9]   Epidemiologic study on Kawasaki disease in Beijing from 2000 through 2004 [J].
Du, Zhong-Dong ;
Zhao, Di ;
Du, Junbao ;
Zhang, Yong-Lan ;
Lin, Yao ;
Liu, Chong ;
Zhang, Tuohong .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (05) :449-451
[10]   Kawasaki syndrome in Denmark [J].
Fischer, Thea K. ;
Holman, Robert C. ;
Yorita, Krista L. ;
Belay, Ermias D. ;
Melbye, Mads ;
Koch, Anders .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (05) :411-415